A Phase 2 interventional study of SMP-656 Injection and SMP-656 Injection in HER2-positive Breast Cancer, Metastatic Breast Cancer and Locally Advanced Breast Cancer (LABC), sponsored by Chengdu SciMount Pharmatech Co., Ltd.. Recruiting at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Chengdu SciMount Pharmatech Co., Ltd. · Phase 2, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,936 studies in Breast Neoplasms with a site in China — 871 open to participants now, 1,068 under way, 211 of them phase 3. Breast Neoplasms · China.
Among the 1,936 studies in Breast Neoplasms with a site in China, this one is the 1,056th largest by planned enrollment of the 1,525 interventional ones that give a count, is one of 192 that started in 2026, is one of 494 in phase 2, reaches primary completion later than 687 of the 1,067 other live ones, and was the 1,865th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →871 of the 1,936 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18–70 · Women only
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–70 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
Fudan University · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18+ · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,936 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 281 · Phase 2 643 · Phase 3 372 · Phase 4 51
First in 1997; this study’s year is marked. 192 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 1,525 interventional studies, 240 across the 409 observational. Of the 451 that completed or were terminated, 77 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
490 of 1,936 have an industry lead sponsor. The 10 most frequent:
Chengdu SciMount Pharmatech Co., Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Chengdu SciMount Pharmatech Co., Ltd. has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
248 of the studies in Breast Neoplasms with a site in China that are under way reach primary completion within a year, 42 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06954961Phase 3InventisBio Co., LtdA Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | 2026-11-30 |
| NCT06968585Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy | 2026-11-30 |
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT04290793Phase 3Hebei Medical University Fourth HospitalNeoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | 2026-12-01 |
Add all 248 to your calendar (.ics) → With an account.
Among the 1,936 studies in Breast Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if single-agent SMP-656 works to treat patients with HER2-positive locally advanced or metastatic breast cancer who have progressed after prior HER2-targeted topoisomerase inhibitor antibody-drug conjugate (ADC) treatment. It will also evaluate the safety of SMP-656 and identify the optimal dose for future trials. The main questions it aims to answer are:
What is the objective tumor response rate (DOR, PFS, DCR, OS) of two different dose regimens of intravenous SMP-656? What are the side effects and safety risks of these two SMP-656 dose regimens? Which dose level achieves the best balance of anti-cancer activity and tolerability? This is a randomized, open-label, dose-optimization Phase II clinical trial. Participants will be randomly assigned 1:1 to receive one of two fixed doses of SMP-656 given intravenously once every 3 weeks.
Participants will:
Complete screening tests within 28 days before the first SMP-656 infusion to confirm eligibility Receive study treatment every 3 weeks until cancer progression, intolerable side effects, withdrawal, or other stopping criteria Have regular tumor imaging scans, physical exams, vital sign checks, and blood tests to monitor tumor response and safety Attend a safety follow-up visit 30 days after the last dose of SMP-656 Complete longer-term survival follow-up after the 30-day safety check Provide optional blood and tumor tissue samples for additional research studies
This is a randomized, open-label, dose-optimization Phase II clinical trial to assess the efficacy and safety of single-agent SMP-656 in patients with HER2-positive unresectable locally advanced or metastatic breast cancer who progressed after prior HER2-targeted topoisomerase inhibitor ADC therapy.
The trial plans to enroll approximately 45-60 participants. Eligible participants must have received one prior HER2-targeted topoisomerase inhibitor ADC (e.g., DS-8201 or other ADCs with topoisomerase inhibitor payloads) and experienced disease progression (single-agent endocrine therapy excluded).
Two dose cohorts selected based on Phase I data: 2.0 mg/kg and 2.2 mg/kg. Participants will be randomized 1:1 to each dose cohort, with 15 subjects enrolled per cohort in Stage 1. An interim analysis will be conducted after Stage 1 enrollment completion:
The investigational product will be administered intravenously once every 3 weeks (Q3W). All participants will receive long-term treatment until the first occurrence of any of the following events: intolerable toxicity, disease progression (judged by the investigator that further treatment cannot provide clinical benefit), loss to follow-up, death, voluntary withdrawal, or study completion/early termination of the trial, whichever comes first.
A Safety Review Committee (SRC) will be established for this trial. Based on the results of interim analysis assessments, the SRC shall judge and determine the further research of each dose group, and make decisions on the key clinical trial doses.
The study consists of a screening period (from the time participants sign the informed consent form up to prior to the first study drug administration, with a maximum duration of 28 days), a treatment period (from the first study drug administration to permanent discontinuation of study drug), and a follow-up period (post-discontinuation safety follow-up and survival follow-up).
During the treatment period, all participants shall undergo tumor imaging assessments every 6 weeks (±7 days) starting from the first dose administration. Imaging assessments will not be affected by interrupted or delayed study drug administration. Investigators will assess antitumor efficacy in accordance with Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Assessments will continue until the earliest occurrence of any of the following events: disease progression, withdrawal of informed consent, loss to follow-up, death, initiation of new antitumor therapy, or trial conclusion (including trial completion and early trial termination), whichever comes first.
Safety Follow-up All participants shall complete a safety follow-up visit at 30 days ± 7 days after the last dose of the investigational product.
If the End of Treatment (EOT) visit for early discontinuation or treatment completion coincides with the scheduled safety follow-up timepoint, duplicate assessments are not required.
If the actual completion date of the early discontinuation/treatment completion (EOT) visit falls beyond the scheduled safety follow-up window due to objective reasons (e.g., delayed dosing), duplicate assessments are also not required. Failure to complete the dedicated safety follow-up in such circumstances shall not be deemed a protocol deviation (PD).
Survival Follow-up After completion of the safety follow-up, investigators will collect survival information for all participants every 3 months (±14 days) via telephone interviews, review of participants' medical records or outpatient medical files. Survival follow-up will continue until any of the following occurs: withdrawal of informed consent by the participant, loss to follow-up, death, or trial termination.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1) Endocrine monotherapy is excluded from the abovementioned standard therapy lines; 2) Disease recurrence occurring within 12 months following or adjuvant chemotherapy will be regarded as progression after standard therapy; 6. Have at least one measurable target lesion per the Version 1.1 (RECIST 1.1) .
7. performance status 0-1. 8. Expected survival ≥ 3 months. 9. Bone marrow, hepatic, renal and coagulation function shall be deemed adequate based on laboratory tests performed within 7 days prior to the first dose of the product. Blood transfusion or growth factor supportive therapy is prohibited within 14 days before the first administration of the investigational product:
Coagulation function: (INR) ≤ 1.5 × ULN, and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
10. Women of (WOCBP) must agree to use highly effective or maintain abstinence from the time of informed consent signature through 6 months after the last administration of the investigational product;For WOCBP, serum pregnancy testing performed within 7 days prior to the first dose of the investigational product must yield a negative result.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SMP-656 2.0 mg/kg Q3W
Drug: SMP-656 Injection
SMP-656 2.2 mg/kg Q3W
Drug: SMP-656 Injection
SMP-656 injection administered via intravenous infusion at a dose of 2.0 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.
SMP-656 injection administered via intravenous infusion at a dose of 2.2 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.
Objective Response Rate (ORR) assessed by Independent Review Committee (IRC)
ORR is the percentage of evaluable patients with an IRC-assessed response of complete response (CR) or partial response (PR) per RECIST v1.1.
Time frame: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)
Recommended Dose in Pivotal Clinical Trials
Determination of pivotal trial recommended dose based on drug exposure, efficacy, and safety profiles across different dose levels.
Time frame: Through study completion, up to 24 months from first dose
ORR assessed by Investigators
Investigator-assessed ORR is the percentage of evaluable patients with a confirmed investigator-assessed response of CR or PR per RECIST v1.1.
Time frame: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)
Duration of Response (DOR)
DOR is the time from the date of first documented confirmed objective response (CR or PR per RECIST v1.1) until the date of disease progression or death.
Time frame: From first confirmed objective response (CR/PR) up to 24 months from first dose
Progression-Free Survival (PFS)
PFS is the time from the date of first dose until the date of objective radiographic disease progression or death (by any cause in the absence of progression).
Time frame: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)
Disease Control Rate (DCR)
DCR is the investigator-assessed percentage of evaluable participants with confirmed CR (complete response), PR (partial response), or SD (stable disease) per RECIST v1.1.
Time frame: Up to 24 months from first dose
Overall Survival (OS)
OS is the time from the date of first dose until the date of death by any cause.
Time frame: From treatment initiation until death from any cause, assessed up to 60 months.
Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) / Serious Adverse Events (SAEs)
Frequency, type, and maximum grade of all AEs and SAEs graded per NCI CTCAE Version 6.0
Time frame: From enrollment through 30 days after last study drug administration, up to 24 months
Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
Maximum Plasma concentration (Cmax) of SMP-656 and total anti-HER2 antibody is assessed.
Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of Free Eribulin Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
Maximum Plasma Concentration (Cmax) of free eribulin is assessed.
Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Pharmacokinetic Parameter Time to Maximum Serum Concentration (Tmax) Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
Time to maximum serum concentration (Tmax) of SMP-656 and total anti-HER2 antibody is assessed.
Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Pharmacokinetic Parameter Time to Maximum Serum Concentration (Tmax) of Free Eribulin Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
Time to maximum serum concentration (Tmax) of free eribulin is assessed.
Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
AUC from time zero to the last quantifiable concentration (AUC0-last) and AUC over one dosing interval (AUC0-tau) of SMP-656 and total anti-HER2 antibody are assessed.
Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of Free Eribulin Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
AUC from time zero to the last quantifiable concentration (AUC0-last) and AUC over one dosing interval (AUC0-tau) of free eribulin is assessed.
Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Exposure-Efficacy and Exposure-Safety (E-R) Relationships
Exposure-response (E-R) analysis evaluating correlations between exposure of conjugated SMP-656, total antibody, free eribulin and efficacy/safety endpoints.
Time frame: Each cycle is 21 days. Exposure, efficacy and safety data are collected during Cycle 1-5 and subsequent odd maintenance cycles, at the occurrence of SAEs or Grade ≥3 TRAEs, and through 30 (±7) days following the last study dose. (up to 24 months)
Exposure-Efficacy and Exposure-Safety (E-R) Relationships
Exposure-response (E-R) analysis evaluating correlations between exposure of conjugated SMP-656, total antibody, free eribulin and efficacy/safety endpoints.
Time frame: From Cycle 1 through all odd maintenance cycles, 30 days after last dose, and at onset of serious adverse event or Grade ≥3 treatment-related adverse event
Immunogenicity of SMP-656
Incidence and magnitude of anti-drug antibody responses to SMP-656
Time frame: Each cycle is 21 days. Immunogenicity sampling is conducted within 1 hour pre-dose on C1D1, C2D1, C3D1, C5D1, and every 4 subsequent cycles. Additional sampling is done for SAEs/Grade ≥3 TRAEs, and 30 days after the last dose. (up to 24 months)
Genomic and Microenvironment Molecular Alterations Associated With SMP-656 Resistance
Baseline and post-treatment genomic, circulating biomarker and tissue spatial microenvironment profiles of blood and tumor samples, including ctDNA, circulating proteins, exosomes, and tissue microenvironment features.
Time frame: Baseline and end-of-treatment (EOT) visit. EOT sampling is performed within 7 days after treatment discontinuation and prior to any new antitumor therapy, up to 24 months from first dose.
Multi-Omics Biomarker Profiles Correlated With Clinical Efficacy and Prognosis
Multi-omics profiles of blood and tumor samples, including ctDNA, plasma proteomics, single-exosome profiling, tissue spatial transcriptomics/proteomics, and tissue genomic features.
Time frame: Baseline and EOT visit. EOT sampling is performed within 7 days after treatment discontinuation and prior to any new antitumor therapy, up to 24 months from first dose.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 10 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chengdu SciMount Pharmatech Co., Ltd.